The level of income appears to have no consistent bearing on pharmaceutical prices across countries
- PMID: 21821572
- DOI: 10.1377/hlthaff.2010.0317
The level of income appears to have no consistent bearing on pharmaceutical prices across countries
Abstract
A generally accepted view is that it is more efficient and ethical if global pharmaceutical prices vary according to countries' relative income. To understand manufacturers' pricing strategies, we compared average pharmaceutical prices in fourteen middle-income countries to those in three high-income countries and a low-income region in western Africa from 1999 through 2008. We found that some middle-income countries pay more for pharmaceuticals than high-income countries--for example, prices in several middle-income countries exceeded those in the United Kingdom for some years of the study period. Other middle-income countries paid less than low-income countries--for example, average prices in India were consistently below prices in western Africa. These variations suggest that we need new policies on pharmaceutical pricing to improve access to pharmaceuticals around the world.
Similar articles
-
[Risk sharing methods in middle income countries].Acta Pharm Hung. 2012;82(1):43-52. Acta Pharm Hung. 2012. PMID: 22570986 Review. Hungarian.
-
Prices of pharmaceuticals in poor countries are much lower than in wealthy countries.Health Aff (Millwood). 2011 Aug;30(8):1553-61. doi: 10.1377/hlthaff.2009.0923. Health Aff (Millwood). 2011. PMID: 21821573
-
Pharmaceutical companies' variation of drug prices within and among countries can improve long-term social well-being.Health Aff (Millwood). 2011 Aug;30(8):1539-44. doi: 10.1377/hlthaff.2010.0891. Health Aff (Millwood). 2011. PMID: 21821571
-
Differential pricing of new pharmaceuticals in lower income European countries.Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):735-41. doi: 10.1586/14737167.2013.847367. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 24219049 Review.
-
Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries.Health Aff (Millwood). 2011 Aug;30(8):1529-38. doi: 10.1377/hlthaff.2010.0902. Health Aff (Millwood). 2011. PMID: 21821570
Cited by
-
Implementing precision oncology in Latin America to improve patient outcomes: the status quo and a call to action for key stakeholders and decision-makers.Ecancermedicalscience. 2024 Jan 8;18:1653. doi: 10.3332/ecancer.2024.1653. eCollection 2024. Ecancermedicalscience. 2024. PMID: 38425763 Free PMC article.
-
Addressing the unmet needs of patients with BRAF-mutated melanoma in Latin America: Expert perspective.Front Oncol. 2023 Mar 14;13:1032300. doi: 10.3389/fonc.2023.1032300. eCollection 2023. Front Oncol. 2023. PMID: 36998456 Free PMC article. Review.
-
Improving access to SLE therapies in low and middle-income countries.Rheumatology (Oxford). 2023 Mar 29;62(Suppl 1):i30-i35. doi: 10.1093/rheumatology/keac530. Rheumatology (Oxford). 2023. PMID: 36987603 Free PMC article. Review.
-
Precision oncology in Latin America: current situation, challenges and perspectives.Ecancermedicalscience. 2019 Apr 3;13:920. doi: 10.3332/ecancer.2019.920. eCollection 2019. Ecancermedicalscience. 2019. PMID: 31281417 Free PMC article.
-
Analysis of prices paid by low-income countries - how price sensitive is government demand for medicines?BMC Public Health. 2014 Jul 30;14:767. doi: 10.1186/1471-2458-14-767. BMC Public Health. 2014. PMID: 25073407 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
